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1. Introduction 
Inflammatory bowel disease (IBD) is a chronic, relapsing disease of the gastrointestinal 
(GI) tract of uncertain origin. Its two main phenotypes are Crohn’s disease (CD) and 
ulcerative colitis (UC). CD affects any part of the GI tract and is characterized by 
transmural inflammation, whereas UC is confined to the colon and affects only the 
mucosal layer. IBD is thought to occur in genetically predisposed individuals that develop 
an abnormal immune response to enteric bacteria in the intestinal mucosa (Podolsky, 
2002; Xavier RJ & Podolsky, 2007). Disease occurs as a result of complex and dynamic 
interactions between immune and non-immune cells as well as the cross-talk between 
intestinal epithelium and mesenchyme (Danese, 2011; MacDonald et al., 2011; Strober & 
Fuss, 2011). Therefore, factors that are able to influence both interactions may be very 
important for the pathogenesis and treatment of IBD.  
Bone morphogenetic proteins (BMPs) are a large group of structurally related proteins that 
belong to the transforming growth factor-β (TGF-β) superfamily. Along with their primarily 
osteogenic function their importance in development, proliferation and morphogenesis of a 
variety of cells and tissues has been shown (Hogan, 1996; Vukicevic et al., 1989; 1995; 
Wozney et al., 1988). In addition, association of BMPs with healing processes of different 
non-skeletal tissues and organs was also described (Lories et al., 2005; Martinovic et al., 
2002; Nguyen et al., 2008; Simic & Vukicevic, 2004; Turk et al., 2009; Vukicevic et al., 1996; 
Vukicevic & Grgurevic, 2009). Due to their wide-range of effects, they are commonly named 
“body morphogenetic proteins” (Reddi, 2005). Perturbations in BMP expression and BMP 
signaling pathway have been associated with the pathological conditions linked to several 
human diseases such as inflammatory bowel disease (IBD) (Allaire et al., 2011; Burke et al., 
2007; Krishnan et al., 2011). 
In this chapter we will discuss the importance of BMPs in gut development and hereditary 
diseases as well as their influence on cellular and molecular events that occur in IBD and 
fibrogenesis, the most common complication of IBD. Furthermore, we will address the 
therapeutical potential of BMPs, especially BMP7 in treatment of IBD. Finally, we will 
explore the possibility of BMP pathway components as putative biomarkers of gut tumor 
development and progression.  
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2. Bone morphogenetic proteins  
BMPs comprise a group of very important signaling molecules, which is demonstrated by 
the the fact that several of these proteins, as well as their intracellular signaling components 
have been conserved in Drosophila and Caenorhabditis elegans. They are originally isolated 
from bone and major contribution to their isolation and characterization was made by 
Sampath and Reddi (Sampath & Reddi, 1981; Sampath et al., 1987). BMPs are a large family 
within the transforming growth factor β (TGFβ) superfamily. Twenty BMP family members 
have been isolated and characterized so far. BMPs are divided into 4 groups based on their 
structure and function: the BMP2/4 group consists of BMP2, BMP4 and  Decapentaplegic 
(dpp) in Drosophila,  the OP-1 group is made up of BMP5, BMP6, BMP7 or osteogenic 
protein (OP1), BMP8 (OP2) and 60A in Drosophila,  the GDF5 group includes the growth-
differentiation factor-5 (GDF5) or cartilage-derived morphogenetic protein-1 (CDMP1), 
GDF6 (CDMP2 or BMP13) and GDF7 (BMP12), and finally the forth group includes BMP9 
and BMP10 (Miyazono, 2000; Miyazono et al., 2010). Grouping of BMPs is continually 
subject to changes due to studies which reveal their structure.   
 
 
Fig. 1. TGFβ superfamily (according to Celeste et al., 1990). 
BMPs are 30-38 kDa dimeric molecules. Their structure is very important for biological 
activity in vivo. They are synthesized as large precursor proteins in the cytoplasm that are 
proteolytically processed to yield mature proteins (Kingsley, 1994). Mature BMP 
molecules are characterized by the formation of a cysteine knot with the seven conserved 
cysteine domains. Active form of the molecule is dimeric as a homodimer or heterodimer 
(Rueger, 2002).  
BMPs transduce their signals by binding to two different transmembrane serine/threonine 
kinase receptors, type I (BMPRI) and type II (BMPRII).  Three type I and three type II 
receptors are identified for BMP ligand binding (Fig. 2). Type I receptors include activin 
receptor type IA (ActRIA or ALK2) and BMP receptors type IA and IB (BRIA or ALK3; BRIB 
or ALK6), while type II receptors are BMP receptor type II (BRII), activin receptor type IIA 
and IIB (ActRIIA and ActRIIB) (Miyazono et al., 2005, Sieber et al., 2009). Receptors form 
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heteromeric complexes and activate downstream signaling molecules through Smad and 
non-Smad signaling pathway (Fig. 3) (Korchynskyi & ten Dijke, 2002; Massague et al., 2005; 
Miyazono et al., 2005). Both receptors are required to activate the signaling pathway. By 
BMP ligand binding, type II receptor phosphorylates the type I receptor which propagates 
the signal (Massague et al., 2005, Wrana et al., 1994).  
 
     
              (a) BMP-receptors                            (b) BR-Smad and AR-Smad proteins 
Fig. 2. Components of TGFβ/BMP signaling pathway  
The intracellular mediators of BMP signaling transduction are Smad transcription factors. 
Smad is named after human Sma1 assessment and its identification with similar genes 
found in Drosophila (Drosophile mothers against dpp – Mad) and Caenorhabditis elegans 
(Sma) (Liu et al., 1996). Three subclasses of Smad proteins have been described based on 
their structure and function: receptor regulated Smads (R-Smads), common mediator Smad 
(co-Smad), and inhibitory Smads (I-Smads) (Fig. 2). R-Smads are further subdivided into 
BR-Smads referred to as BMP signaling (Smad1/5/8) and AR-Smads referred to as 
activin/TGFβ signaling (Smad2/3). They are phyosphorylated by the type I receptors, 
interact with co-Smad (Smad4) and translocate into the nucleus initiating transcription of 
BMP response genes (Kawabata et al., 1998; Miyazono et al., 2010). Inhibitory Smads (I-
Smad6/7) compete with R-Smads for the activated type I receptor binding site. Smad7 
inhibits both activin/TGFβ and BMP signaling pathway while Smad6 preferentially inhibits 
BMP signaling (Hanyu et al., 2001).  
BMP signaling is controlled also by soluble BMP antagonists. They exert their function by 
direct binding of BMPs and prevent functional receptor/ligand interaction (Lein et al., 2002; 
Piccolo et al., 1996; Yanagita, 2005; Zimmerman et al., 1995). Several structurally distinct 
classes of inhibitory BMP binding proteins have been described in vertebrates: twisted 
gastrulation (TSG), chordin and noggin and the DAN-family of inhibitors. The DAN family 
includes a large number of members such as DAN, cerebrus, protein related to DAN and 
cerebrus (PRDC), gremlin, Cer1, USAG-1 and sclerostin (Bouwmeester et al., 1996; Hsu et al., 
1998; Stanley et al., 1998). They bind different BMPs with various degrees of affinity and 
specifity. For instance, noggin and chordin bind BMP2 and -4 with higher affinity than BMP7 
whereas sclerostin binds with greater affinity BMP6 and -7 (Lein et al., 2002; Yanagita, 2005).  
3. BMPs and their signaling pathway in gastrointestinal tract 
3.1 BMPs and their signaling pathway in gastrointestinal tract development 
BMPs and their signaling pathways are important for the normal development of the 
gastrointestinal tract. They are active from the earliest stage of development and revealed to 
be essential for the intestinal growth and morphogenesis. It has also been shown that BMP  
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Fig. 3. BMP signaling pathway (with kind permission from Springer Science+Business 
Media: Bone morphogenetic proteins: from laboratory, to clinical practice, Bone 
morphogentic protein receptors and their nuclear effectors in bone formation, 2002, pp.  31–
60, Korchynskyi, O. & ten Dijke, P. Fig. 3) 
signaling is a mediator in epithelial and mesenchymal stroma interaction which is required 
for the intestinal growth, morphogenesis, differentiation and homeostasis (Batts et al., 2006; 
de Santa Barbara et al., 2005). Initial investigation of the BMP expression in the GI tract 
showed limited expression of individual BMP and its receptors during development. BMP6 
and BMP7 were found in the developing human and mouse intestine limiting its expression 
to the smooth muscle cells and intestinal epithelium, respectively (Helder et al., 1995; Perr et 
al., 1999). Expression of BMP type I receptor (ALK6) was found in the stomach and its 
pyloric region (Dewulf et al.,1995). It has also been noticed that villus formation depends on 
high BMP2 and -4 expressions in the condensed mesenchyme underlying sites of future 
villus formation and may inhibit crypt formation in the overlying epithelium (Karlsson et 
al., 2000). In addition, BMP2 and its receptors (IB and II) were expressed in the smooth 
muscle progenitors of mouse embryonic GI tract with evident BMP2-induced smooth 
muscle differentiation and phenotype (Goldman et al., 2009). 
De Santa Barbara et al. (2005) noticed that the BMP signaling pathway showed wider 
expression than BMP ligands in the chick developing gut. This pathway is activated in all three 
tissue layers of the GI tract, allowing interaction and reciprocal communication.  The BMP 
signaling activity was found in the mesoderm during the differentiation into visceral smooth 
muscle and was downregulated by the completion of this process. A similar observation was 
made for the enteric nervous system (ENS) during its derivation of the ectoderm. BMP 
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signaling activity is detected also in the endoderm, future epithelium with prominent delay of 
BMP signaling activation in the colon. Inhibition of BMP activation by Bapx1 misexpression in 
the chick gut mesoderm results in diminished influence of mesoderm to endoderm-ectoderm 
signaling. This leads to an altered gut phenotype with marked muscular hypertrophy followed 
by abnormality in the ENS and epithelium.  Decreased BMP signaling in mice overexpressing 
the BMP-antagonist noggin leads to abnormal villus morphogenesis of mouse proximal 
intestine. This was associated with stromal and epithelial hyperplasia, and ectopic crypt 
formation due to low levels of BmprIA and pSmad1/5/8 (Batts et al., 2006).  A similar 
abnormal phenotype was found in the large intestine. These results suggest that BMP 
signaling restricts the site of crypt formation to the intervillus region and normally suppresses 
crypt formation in the villus. Human GI diseases which are accompanied by abnormal 
intestinal morphology, like JP or ENS disorder and even more chronic intestinal diseases 
associated with muscular hypertrophy such as Hirschprung’s disease, could be associated 
with defects in the BMP signaling pathway (Amiel & Lyonnet, 2001; He et al., 2004).   
3.2 BMPs and their signaling pathway in the normal gastrointestinal tract  
BMPs and their signaling pathway are expressed in normal intestine and colon. It was 
shown that BMP2, the BMP receptors (Ia, Ib, II), phosphorylated Smad1 and Smad4 are 
present in mature colonocytes at the epithelial surface of normal human and mouse colon 
(Hardwick et al., 2004). The expression of BMP receptors was also found in colonic epithelial 
cell lines and BMP2 treatment in vitro resulted in inhibition of proliferation and induction of 
apoptosis. BMPRIA and BMP2 are highly expressed in the villus epithelium and 
distal/surface epithelium of the adult mouse small and large intestine with increase 
expression in stroma and crypt epithelium (Batts et al., 2006; Haramis et al., 2004). BMP4 is 
expressed in stromal cells and mesenchimal cells surrounding the crypt and glands of the 
small and large intestine (Haramis et al., 2004; He et al., 2004).  
The expression profile of genes in the mouse intestine showed a difference between the 
expression of BMP signaling components in the epithelium and mesenchyme (Li et al., 
2007).  BMP signaling is observed in both epithelial and mesenchymal compartments, 
though studies to date have primarily addressed epithelial signal transduction (He et al., 
2004). BMP2, BMP4, BMP5, BMP6 and BMPRII are expressed in mesenchymal 
compartments while only BMP7 showed epithelial enrichment. BMP7 was present in surface 
epithelial cells and crypts of the normal colon mucosa (Grijelmo et al., 2007). BMP receptors 
type I (BMPRIA or ALK3 and Acvr1 or ALK2) are present in mesenchymal compartments 
while the expression of BMPRIB (ALK6) was found in both compartments. Smads are 
expressed in both epithelial and mesenchymal compartments with slight enrichments in the 
mesenchyme while Smad4 expression was approximately equal in both compartments. 
Along the colon crypt, a different pattern of Smad4 expression was observed with high 
expression in the zone of terminal differentiation (Korchynskyi et al., 1999). 
Apart from noggin, the BMP pathway inhibitors are located exclusively in the mesenchyme. 
The gene expression analysis of normal human colon tops and basal crypts revealed 
difference in nine hundred and sixty-nine cDNA clones from these two compartments 
(Kosinski et al., 2007). BMP1, BMP2, BMP5, BMP7, SMAD7 and BMPRII were highly 
expressed in colon tops while expression of the BMP antagonists gremlin 1, gremlin 2 and 
chordin-like 1 was found in basal colon crypts originating from myofibroblasts and smooth 
muscle cells (Fig. 4). It was also shown that activation of extracellular calcium-sensing 
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receptor (CaSR), expressed on the epithelia of the GI tract and myofibroblasts, 
downregulated BMP4 and noggin expression and raises the effective concentration of BMP2 
leading to increased intestine repair and barrier development (Peiris et al., 2007).  
 
 
Fig. 4. BMP signaling components in compartments of the normal colon crypt (from 
Kosinski et al. (2007). Gene expression patterns of human colon tops and basal crypts and 
BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA 104:15418-
15423.  Copyright (2007) National Academy of Science, U.S.A. Used with kind permission).  
3.3 BMPs and TGFβ/BMP signaling pathway in inflammatory bowel disease 
Animal models of colitis are often used to aid in IBD research. They allow a detailed 
examination of the pathological process from acute to chronic phase, providing an insight into 
the immunological disturbances behind the pathogenesis of IBD (Hibi et al., 2008; Mizoguchi 
& Mizoguchi, 2010; Shi et al., 2011). In these animal models colitis can be induced by chemical, 
immunological, microbiological and physical factors (Boirivant et al., 1998; Morris et al., 1989; 
Okayasu et al., 1990). There are also transgenic and knock-out mouse strains that develop 
colitis, as well as spontaneous colitis models (Matsumoto et al., 1998; Mombaerts et al., 1993; 
Sadlack et al., 1993; Sundberg et al., 1994). Chemically induced colitis is one of the most 
utilized animal models. Dextran sulfate sodium (DSS), a heparin-like polysaccharide is often 
used to induce a UC-like colitis because of its simplicity and reproducibility of the 
inflammatory intestinal lesions. In the intestine of DSS treated mice epithelial barrier 
disruption with neutrophil and macrophage infiltration is observed as well as abnormal 
www.intechopen.com
 Bone Morphogenetic Proteins and Signaling Pathway in Inflammatory Bowel Disease 
 
205 
cytokine production (Dieleman et al., 1994; Kitajima et al., 1999). Trinitrobenzene sulfonic acid 
(TNBS) dissolved in ethanol induces a CD-like colitis, with transmural inflammation (Elson et 
al., 1995).  Ethanol is thought to cause a transient increase in intestinal permeability, allowing 
TNBS to invade the musocal layers and act as a hapten to form complete antigens with tissue 
proteins. This provokes an intense and sustained inflammatory response and breaks T-cell 
tolerance to mucosal antigens (Boismenu & Chen, 2000). Genetic colitis models such as gene 
knockout and transgene models offer another approach in experimental IBD research. They 
imply genetic modifications that favor the development of colitis. IL-2 deficient mice 
spontaneously develop a UC-like colitis in 100% of cases, while mice lacking the IL-10 gene 
develop chronic colitis only in the presence of enteric bacteria (Kuhn et al., 1993; Sadlack et al., 
1993). Other genetic models include T cell receptor, STAT3 and IL-17 gene manipulation 
(Alonzi et al., 2004; Hibi et al., 2002; Mombaerts et al., 1993).  
Monteleone et al. (2001) were among the first groups to show the disturbance of the TGF-┚1 
signaling pathway in human IBD. They found that Smad7, an inhibitor of BMP-signaling, 
was overexpressed, whereas Smad3, an R-Smad of this signaling pathway, was 
downregulated.  Due to Smad7 inhibition, lamina propria mononuclear cells (LPMC) 
isolated from mucosa of CD patients were not able to respond to TGF-┚1 and to 
downregulate proinflammatory cytokine expression, especially of TNF┙ and IFN┛. 
Moreover, Smad7 inhibition by specific antisense oligonucleotides allowed LPMC to 
respond to TGF-┚1 restoring TGF-┚1 signaling by increasing pSmad3 and decreasing 
Smad7, and provide TGF-┚1-mediated inhibition of proinflammatory cytokine production 
in experimentally induced colitis (Boirivant et al., 2006). Previously, it was shown that mice 
with targeted disruption of the TGF-┚1 gene or one of its intracellular signaling components 
develop multifocal inflammation (Shull et al., 1992). High expression of Smad7, as seen in 
IBD mucosa, was a consequence of deregulated post-translational modification. Various 
proteins were shown to be involved, including Smurfs, the transcriptional coactivator p300, 
Arkadia  and Jun activation domain-binding protein 1, which regulate Smad7 nuclear export 
and/or make the protein resistant to proteasome-mediated degradation (Monteleone et al., 
2004a; 2004b; 2005). Targeted blocking of Smad7 gene expression was shown to be an 
effective way to attenuate the ongoing intestinal inflammation (Monteleone et al., 2008).  
The R-Smad, Smad3 plays an important role in TGF┚ signaling. Smad3 heterozygous 
mice, characterized by reduced levels of Smad3, showed accelerated healing of colonic 
mucosa after experimental induction of colitis with TNBS. The most prominent effects 
were on re-epithelization and proliferation of the intestinal epithelium, which was 
associated with reduced production of TGF-┚1 (Tokumasa et al., 2004). Another molecule 
of this pathway, CTGF, which acts as a downstream effector of the TGF┚ signaling 
pathway, was markedly increased in almost 90% of CD tissue samples. CTGF expression 
is mostly localized in fibroblasts of the submucosal layer while completely lacking in 
inflammatory cells (di Mola et al., 2004). More recently, it has been reported that 
deficiency of Smad5 in intestinal epithelial cells leads to an increase of cell migration and 
villus lengthening followed by disassembly of the apical junctional complex (Allaire et al., 
2011). This intestinal epithelial impairment makes Smad5∆IEC mice more susceptible to 
DSS colitis development and reduced healing.  Decreased expression of the BR-Smad, 
Smad5 was also found in intestinal samples from IBD patients, which emphasizes the 
importance of BMP signaling in IBD.  
Several growth factors like TGFβ superfamily, growth hormone, epidermal growth factor, 
keratinocyte growth factor, teduglutide and granulocyte macrophage/granulocite colony 
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stimulating factors have been involved in clinical studies so far (Krishnan et al., 2010). BMPs 
as osteoinductive agents are mostly implemented in healing bone damage but the presence 
of their expression during development and in adulthood indicates their importance during 
different disease and healing processes. We have previously shown the accumulation of 
radioactively labeled BMP7 in the GI tract primarily in stomach and intestine with the 
highest uptake in terminal ileum (Fig. 5)(Maric et al., 2003).  
 
 
Fig. 5. Biodistrubution of 125I-labeled BMP7 in rat gastrointestinal tract. Rats were analyzed 
at different time points following i.v. injection of 125I-BMP7 (injected dose was 25 µCi/0.791 
µg/kg). Relative uptake of 125I-BMP7 was expressed as ng of radiolabeled BMP7/g wet 
tissue weight (Maric et al., 2003).  
In addition, systemically applied BMP7 reduced the macroscopic and microscopic changes 
observed in TNBS-induced colitis followed by downregulation of proinflammatory cytokines 
(i.e. IL-6, TNFα, ICAM-1) and pro-fibrogenic cytokines (i.e. TGF┚). BMP7 accelerated healing 
of wounded tissue and reduced neutrophil infiltration (Fig. 6, Fig. 7 & Fig. 8).   
 
     
                         (a) TNBS-colitis                                  (b) TNBS-colitis upon BMP7 treatment 
Fig. 6. Macroscopic appearance of colonic mucosa during different days of experimentally 
induced colitis.  The cobblestone-like ulceration in acute (days 2 and 5) and linar ulceration 
in chronic (days 14 and 30) stage was evident in colon. BMP7, applied systemically reduced 
macroscopic colon damage.    
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     (a) Acute stage of colitis         (b) Chronic stage of colitis           (c) BMP7 treatment  
Fig. 7. Representative histological sections of colon from colitic rats treated with vehicle  
(a, b) and BMP7 (c). Histologic findings in early stage of TNBS-colitis showed intensive 
inflammatory cell infiltration associated with colonic mucosa swelling and bleeding.  In 
chronic stage of TNBS-colitis (b), diffuse infiltration with lymphocytes and fibroblasts was 
observed in ulcus region presenting healing process of colon tissue. The microstructure of 
colon was restored upon therapeutically application of BMP7 (c) Magnification x100.  
BMP2 and BMP7 expression has been found in colon samples during acute and chronic 
stages of experimental colitis.  BMP7 treatment slightly reduced the expression level of 
BMP2 (Maric et al., 2003; 2008). Beneficial effects of BMP7 were also observed in intestinal 
ischemia/reperfusion injury and fibrosis associated with chronic intestinal inflammation 
(Flier et al., 2010; Radhakrishnan et al., 2008).  
3.4 BMP and their pathway in intestinal fibrosis 
Intestinal fibrosis is a major complication of CD disease which is an outcome of multiple 
factors. It occurs as a result of different types of chronic inflammation, initiated in various 
cellular sources, but all result in deregulation of extracellular matrix turnover (Burke 2007, 
Fiocchi & Lund, 2011). TGFβ is described as the most potent profibrotic factor of several  
 
                   
                (a) PCNA  staining                        (b) Naphtol AS-D chloroacetate esterase staining 
Fig. 8. Effect of BMP7 treatment on cell proliferation and neutrophil accumulation in TNBS-
induced colitis. BMP7 significantly reduced cell proliferation and neutrophil accumulation 
upon 14-day long therapy.  
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organs including organs of the GI tract. Experimental studies revealed that disruption of the 
TGFβ/Smad signaling pathway contributed to both chronic tissue inflammation and fibrosis 
(Flanders 2004; Nguyen & Goldschmeding, 2008; Pucilowska et al., 2000; Rieder  et al., 2007). 
Key molecules of this pathway are Smad3 and Smad7. Smad3 null mice exhibit a significant 
reduction of intestinal fibrosis, associated with increased intestinal expression of Smad7 and 
decreased expression of Smad3, CTGF, collagen I-III and TGFβ following TNBS induced 
colitis (Latella et al., 2009; Zanninelli et al., 2006,). Wild-type mice, on the other hand, 
showed decreased expression of Smad7 and increased expression of Smad3, similar to the 
findings of di Sabatino (2009) in biopsies of intestinal strictures from patients suffering from 
Crohn’s disease. Myofibroblasts from mucosa underlying CD strictures produced 
significantly higher amounts of collagen induced by an increased expression of TGFβ and 
Smad2/3 but not Smad7 (di Sabatino et al., 2009). It was pointed out that a disturbance of 
TGFβ/BMP downstream signaling components could contribute to intestinal fibrosis and 
therefore they were presented as more specific antifibrotic targets than TGFβ. Increased 
expression of TGFβ, CTGF, collagen-1α, and BMP7 was found in strictured segments of CD 
intestinal biopsies (Burke et al., 2008), although previous studies showed anti-inflammatory 
and antifibrotic properties of BMP7 (Maric et al., 2003; Flier et al., 2010). The correlation 
between steroid treatment and stricture development in CD was also observed followed by 
increased expression of CTGF in both, in vivo and in vitro by stimulating intestinal 
fibroblasts (Burke et al., 2008). The capacity of BMP7 to antagonize the pro-fibrotic effects of 
TGFβ in various organs including the gut has recently been shown (Fiocchi,  1997; Flier et 
al., 2010; Zeisberg et al., 2005). Treatment with BMP7 inhibits intestinal fibrosis by 
downregulation of TNF and by inhibition of TGFβ-induced epithelial to mesenchymal 
transition of the intestinal epithelial cells, which generates activated fibroblasts and 
contributes to intestinal fibrosis (Flier et al., 2010).  
3.5 BMP and their pathway in other gastrointestinal diseases 
Germline mutations in two members of the BMP pathway have been found to cause juvenile 
polyposis (JP). JP is an autosomal dominant hamartomatous polyposis syndrome. Affected 
individuals are predisposed to upper gastrointestinal and colorectal cancer. In almost half of 
the cases, patients have mutations or deletions in SMAD4 and BMPR1A genes (Howe et al., 
1998; Houlston et al., 1998; Langeveld et al., 2010; van Hattem et al., 2008; Woodford-
Richens et al., 2001; Zhou et al., 2001). Genetic linkage studies of JP patients revealed that 
Smad4 germline mutation was mapped to chromosome 18q21 while BMPR1A germline 
mutations were localized on chromosome 10q22-23 (Howe et al., 1998; 2001).  In a genotype-
phenotype correlation study of JP patients, a significant prevalence of gastric polyposis was 
found in patients with Smad4 mutations when compared to other subsets of patients  
(Friedel et al., 2002). Histologically, JP polyps are characterized by dilated glands, abundant 
stroma and inflammatory infiltrates in a thickened lamina propria with normal epithelial 
covering (Howe et al., 2004). SMAD4 is a known tumor suppressor gene in pancreatic and 
colon cancer, but in JP  it was hypothesized that SMAD4 gene acts as a susceptibility gene, a 
„gatekeeper“, its loss of function resulting in polyp formation through indirect mechanisms, 
suggesting an important role of the stromal inflammatory response in the regulation of 
epithelial tumorigenesis (Moskaluk et al., 1997; Takagi et al., 1996). This theory was 
supported by a study on homozygous Smad4 knockout mice. The most important 
histological findings included thickened intestinal musoca with polyp formation, loss of 
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villus architecture and expansion of the stroma with plasma cell infiltrates, while mice with 
conditional Smad4 deletion in the intestinal epithelial layer did not develop intestinal 
tumors (Kim et al., 2006). In contrast, polyps from JP patients with a germline SMAD4 
mutation showed biallelic inactivation of SMAD4 in both the epithelium and stroma, 
suggesting a common clonal origin (Woodford-Richens et al., 2000).   
Familial adenomatous polyposis (FAP) is an autosomal dominant syndrome characterized by 
hundreds to thousands of adenomatous colorectal polyps that are caused by a deletion in the 
adenomatous polyposis coli (APC) gene, localized on chromosome 5q21. Polyps develop in 
adolescence, and if not treated, malignant alteration inevitably occurs (Morton et al., 1993). 
Extraintestinal manifestations may also be present in form of osteomas, desmoid tumors, 
dental abnormalities and extracolonic cancer (Galiatsatos & Foulkes, 2006). APC gene plays an 
important role in Wnt signaling and is involved in ubiquitine-mediated degradation of ┚-
catenin. Functional defects of APC therefore lead to aberrant Wnt pathway activity, resulting 
in uncontrolled cell proliferation (Rustgi et al., 2007). In intestinal homeostasis, BMP molecules 
have a suppresive effect on Wnt-┚-catenin pathway and preserved BMP signaling is required 
for inhibition of intestinal stem cell proliferation and repression of polyp formation (He et al., 
2004; Haramis et al., 2004). Conversely, higher expression of Wnt signaling molecules in FAP 
results in BMP signaling downregulation. In a study on Wnt target genes, in APC mutant mice  
heterozygous for an allele equivalent to a human APC mutation, more severe polyposis and 
faster rate of tumor growth was associated with higher expression of the BMP antagonist 
Gremlin 1 and  lower BMP2 and BMP4 expression (Lewis et al., 2010). Analogous  results were 
found in human FAP tissue specimens, with BMP2 expression lost in dysplatic epithelium of 
mycroadenomas (Hardwick et al., 2004).  
Association of JP and FAP with the BMP signaling pathway was confirmed by experiments 
on BMP-transgenic mice. Transgenic mice which overexpressed the BMP anatagonist noggin 
or mice with conditional inacativation of BMPRIA which led to disruption of both epithelial 
and mesenchymal BMP signaling,  showed highly increased formation of intestinal polyps 
morphologically similar to those in JP (Haramis et al., 2004; He et al., 2004). Loss of 
mesenchymal BMP signaling by conditional inactivation of BMPRII in stroma led to 
intestinal bleeding, thickness of mucosa due to epithelial hyperplasia and myofibroblast 
increment and multiple hemartomatous polyp appearance (Beppu et al., 2008; Hardwick et 
al., 2008). These expression patterns found in human polyposis syndromes indicate that 
altered BMP expression plays an important role in uncontrolled cell proliferation  and 
tumorigenesis in the intestine.  
Finally, alteration of the BMP signaling pathway may be involved in the appearance of 
intestinal mucosal atrophy due to total parenteral nutrition (Zhang et al., 2009). Expression 
of BMP2, BMP4, BMPRII and pSmad1/5/8 has been found to be increased in intestinal 
mucosa without differences in BMP antagonist expression following parenteral nutrition. 
These alterations were suggested to affect epithelial cell proliferation.   
3.6 BMPs and their pathway in gastrointestinal cancers 
Extensive research was conducted to explore the genes and factors that may trigger the 
initiation and progression of colorectal cancers (Ulman & Itzkowitz, 2011). Among a small 
number of genes known to affect cancer development, BMPs and their signaling pathway have 
been under intensive research during the last decade (van den Brink & Offerhaus, 2007). So far, 
studies have revealed contradictory findings. Some of them have shown reduced or complete 
loss of BMP signaling, while others have shown increased expression of this pathway.  
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Deregulation of mechanisms controlling expression of Smads was found in human 
colorectal cancers characterized by selective up-regulation of R-Smads in tumor cells and 
absence of Smad expression in tumor stroma (Korchynskyi et al., 1999). Co-Smad and I-
Smad were expressed in both tumor and normal tissues. BMP2, BMP3 and BMP7 have been 
found to be growth suppressive for colorectal cancer cells (Beck et al., 2006; Hardwick et al., 
2004; Loh et al., 2008). BMP2 exerts growth suppression by increasing p21WAF1 protein levels, 
inducing p21WAF1 stabilization and not its transcription (Back et al., 2007). BMP/Smad 
independent pathways, like the RAS/ERK-mediated signaling cascade, interferes with 
BMP2-induced p21WAF1 stabilization, thus acting as a negative regulator of BMP signaling 
and arresting growth suppression. The expression of BMPRIA and pSmad1 was found in 
human colon cancer specimens as well as in several cell lines (Beck et al., 2006). The 
consequence of the loss of normal feedback inhibition could be seen in the intestinal 
epithelial cells in JP, where the absence of BMP signaling may lead to enhanced production 
of BMPs in the lamina propria or in epithelial cells (van den Brink, 2004). In addition, the 
loss of BMP signaling could also be connected with tumor progression. BMP4 and BMP7 
expression has been found to increase with progression of the adenoma-carcinoma sequence 
and to correlate with a worse prognosis (Deng et al., 2007, Motoyama et al., 2008). The 
comparison of human adenoma and colorectal cancer specimens revealed the loss of active 
BMP signaling pathway in 9.1% and 77.7%, respectively, (Kodach et al., 2007; 2008a) which 
correlated with tumor progression from late adenoma to early carcinoma. The most 
prominent finding was the loss of BMPRII and Smad4 expression in colorectal carcinoma 
(Hardwick et al., 2008; Kodach et al., 2007; 2008a) which was confirmed by similar findings 
in sporadic colorectal carcinoma. The loss of BMPRII expression was strictly correlated with 
microsatellite instability (Kodach et al., 2008b). On the other hand, it was noticed that BMP 
signaling was regained in more advanced tumor stages (Kodach et al., 2008a).  
Significantly higher BMP7 expression was found in human colorectal cancer than in normal 
tissues. This expression correlated with parameters of pathological aggressiveness and 
poorest prognosis (Motoyama et al., 2008). BMP7 showed a divergent role in different 
pathological changes of colon mucosa (Grijelmo et al., 2007). Whether proinvasive or 
protective activity will prevail depends on the activity of inflammation, tumor type and 
grade and the status of the BMP-Smad dependent and independent pathways. BMP7 and its 
receptors are expressed in normal human colon crypts, aberrant crypt foci in sigmoiditis and 
in half of colorectal tumors. It is involved in cellular scattering and invasion of premalignant 
and carcinoma colon epithelial cells probably by BMP-Smad independent pathways. Recent 
studies have re-emphasized the influence of intact BMP signaling on tumor growth as well as 
on survival and proliferation of colon carcinoma cells in vivo and in vitro (Lorente-Trigos et al., 
2010). The different levels of BMPs (BMP2, BMP4), Smad proteins (Smad1, Smad4, Smad5, and 
Smad8) and absence of BMP inhibitor (chordin and gremlin) expression was found in 
advanced sporadic colon carcinomas. Proliferation and tumor growth of primary colon 
carcinoma cells in vivo can be influenced by altering the activity of BMPRIB. An increase in this 
activity leads to enhanced tumor growth while its inhibition yields the opposite effect. In this 
respect BMPs, as members of TGFβ superfamily, resemble the TGFβ signaling pathway in 
sporadic colorectal cancer (Akiyama et al., 1996; Markowitz et al., 1995). 
4. Conclusion  
BMPs play a vital role in embryogenesis and in tissue homeostasis of numerous organs 
including the GI tract and their malfunction may cause different human disorders.  
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Ubiquitous presence of BMPs and their importance in regeneration of many tissues aroused 
their name from bone morphogenetic protein to body morphogenetic protein (Reddi AH 
2005). The BMP pathway showed complexity by numerous ligands and their antagonists, 
downstream effectors and/or other signaling mediators. In addition, the interaction of the 
BMP pathway with other signaling cascades adds another level of regulation.  
Animal models of IBD provide a valuable tool in IBD research, and are detrimental for the 
understanding of the role of BMP signaling in this family of diseases. Since they are readily 
available and reproducible, they contribute greatly to our knowledge of the complex 
mechanisms of this chronic and debilitating disease and also facilitate the development of 
new therapeutic modalities.  
The BMPs play an important role in a multitude of physiological processes and alterations in 
their signaling properties have been associated with various diseases. These include the 
majority of pathologies of the gastrointestinal tract, among which Crohn’s disease, ulcerative 
colitis and various GI cancers. Not surprisingly, BMP signaling has been under extensive 
investigation as a therapeutic target. We, for example, have previously shown the beneficial 
effects of BMP7 therapy in an experimental model for colitis, with both anti-inflammatory and 
antifibrotic effects on colon damage. In addition, possible targets of the BMP signaling 
pathway for the prevention or treatment of IBD are Smad proteins, including Smad3, Smad5 
or Smad7. However, many of the molecular mechanisms behind their functions are yet to be 
revealed and are currently under our and other people’s investigation.  
In summary, the BMP signaling pathway plays a major role in GI diseases and we therefore 
present it as a group of molecules of high clinical potential for the future.  
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